CN103328501B - 新的生物标记及其在诊断、治疗孤独症中的用途 - Google Patents

新的生物标记及其在诊断、治疗孤独症中的用途 Download PDF

Info

Publication number
CN103328501B
CN103328501B CN201180060249.6A CN201180060249A CN103328501B CN 103328501 B CN103328501 B CN 103328501B CN 201180060249 A CN201180060249 A CN 201180060249A CN 103328501 B CN103328501 B CN 103328501B
Authority
CN
China
Prior art keywords
autism
peptide
sample
seq
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180060249.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103328501A (zh
Inventor
纳吉·莫门尼
本特·L·佩尔松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autism Biodiagnostic Ltd
Original Assignee
Autism Biodiagnostic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autism Biodiagnostic Ltd filed Critical Autism Biodiagnostic Ltd
Publication of CN103328501A publication Critical patent/CN103328501A/zh
Application granted granted Critical
Publication of CN103328501B publication Critical patent/CN103328501B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B20/00—Methods specially adapted for identifying library members
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
CN201180060249.6A 2010-12-16 2011-12-13 新的生物标记及其在诊断、治疗孤独症中的用途 Expired - Fee Related CN103328501B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42363610P 2010-12-16 2010-12-16
US61/423,636 2010-12-16
SE1051330 2010-12-16
SE1051330-7 2010-12-16
PCT/SE2011/051504 WO2012082056A1 (en) 2010-12-16 2011-12-13 Novel biomarker and uses thereof in diagnosis, treatment of autism

Publications (2)

Publication Number Publication Date
CN103328501A CN103328501A (zh) 2013-09-25
CN103328501B true CN103328501B (zh) 2015-09-16

Family

ID=45478452

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180060249.6A Expired - Fee Related CN103328501B (zh) 2010-12-16 2011-12-13 新的生物标记及其在诊断、治疗孤独症中的用途

Country Status (8)

Country Link
US (1) US9347956B2 (https=)
EP (1) EP2651972B1 (https=)
JP (1) JP5960717B2 (https=)
CN (1) CN103328501B (https=)
AU (1) AU2011341776B2 (https=)
CA (1) CA2821908C (https=)
ES (1) ES2580136T3 (https=)
WO (1) WO2012082056A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2014203188A2 (en) * 2013-06-19 2014-12-24 Glaxosmithkline Intellectual Property (No.2) Limited Novel assay
WO2017027709A1 (en) 2015-08-11 2017-02-16 Cognoa, Inc. Methods and apparatus to determine developmental progress with artificial intelligence and user input
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
CN105738631B (zh) * 2016-02-22 2017-10-20 西安交通大学 一种孤独症血清多肽标志物serpina5‑a及其应用
WO2018013811A1 (en) * 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
EP3539033B1 (en) 2016-11-14 2024-10-02 Cognoa, Inc. Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability
CN106596827B (zh) * 2017-01-23 2019-06-07 上海知先生物科技有限公司 Gal指标在自身免疫疾病治疗敏感性和疗效评估中的应用
KR101796891B1 (ko) * 2017-02-08 2017-11-13 재단법인대구경북과학기술원 뇌 시상하부 세포에서 tspo에 의한 대사체 변화 분석방법
WO2018148262A1 (en) * 2017-02-08 2018-08-16 Csp Pharma, Inc. Antipurinergic compounds and uses thereof
US20220254461A1 (en) * 2017-02-09 2022-08-11 Cognoa, Inc. Machine learning algorithms for data analysis and classification
CA3053245A1 (en) * 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
CN118697876A (zh) * 2017-02-09 2024-09-27 完美日光有限公司 用于自闭症谱系障碍药物治疗的方法
GB201802116D0 (en) 2018-02-09 2018-03-28 Univ Warwick Methods for diagnosing an autistic spectrum disorder
EP3773486B1 (en) * 2018-04-04 2023-12-06 Duke University Umbilical cord tissue-derived mesenchymal stromal cells for use in the treatment of autism spectrum disorders
CN109293762A (zh) * 2018-10-17 2019-02-01 湖北民族学院 DRC3f抗原多肽，抗DRC3f的多克隆抗体及应用
CN109813912B (zh) * 2019-01-04 2021-12-28 深圳大学 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用
KR102785528B1 (ko) 2019-03-22 2025-03-21 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
AU2020343020A1 (en) 2019-09-06 2022-03-31 Cognoa, Inc. Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004079371A1 (en) * 2003-03-04 2004-09-16 Forskarpatent I Syd Ab Diagnosis of autism
US20050048584A1 (en) * 2001-11-28 2005-03-03 Norbert Lamping Method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases associated peptides and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617308B2 (en) * 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US6998243B2 (en) * 2001-04-30 2006-02-14 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
US20020160532A1 (en) * 2001-04-30 2002-10-31 George Jackowski Biopolymer marker indicative of disease state having a molecular weight of 1998 daltons
CN102984493B (zh) * 2012-11-21 2016-03-02 华为终端有限公司 视频数据传输的方法、装置及通信设备

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048584A1 (en) * 2001-11-28 2005-03-03 Norbert Lamping Method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases associated peptides and use thereof
WO2004079371A1 (en) * 2003-03-04 2004-09-16 Forskarpatent I Syd Ab Diagnosis of autism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins;Corbett et al.;《Molecular Psychiatry》;20071231;292-306 *

Also Published As

Publication number Publication date
JP2014506244A (ja) 2014-03-13
ES2580136T3 (es) 2016-08-19
EP2651972B1 (en) 2016-04-06
CA2821908A1 (en) 2012-06-21
CA2821908C (en) 2018-09-18
WO2012082056A1 (en) 2012-06-21
JP5960717B2 (ja) 2016-08-02
EP2651972A1 (en) 2013-10-23
AU2011341776A1 (en) 2013-07-04
CN103328501A (zh) 2013-09-25
US9347956B2 (en) 2016-05-24
US20130267441A1 (en) 2013-10-10
WO2012082056A8 (en) 2013-02-14
AU2011341776B2 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
CN103328501B (zh) 新的生物标记及其在诊断、治疗孤独症中的用途
JP2014506244A6 (ja) 自閉症の診断、治療におけるバイオマーカーおよびその使用
US11499982B2 (en) Multi-protein biomarker assay for brain injury detection and outcome
EP2592421B1 (en) Diagnosis of sepsis and systemic inflammatory response syndrome
JP5424331B2 (ja) 肝疾患診断用バイオマーカー
US11478530B2 (en) Methods for decreasing chord length
Priyadharshini et al. Personalized medicine in respiratory disease: role of proteomics
EP3746793A1 (en) Method for the diagnosis of hereditary angioedema
EP3535587B1 (en) Mass spectrometry-based methods for the detection of circulating histones h3 and h2b in plasma from sepsis or septic shock (ss) patients
CN112567039A (zh) 阿尔茨海默氏病的诊断药物和诊断方法
US20230258660A1 (en) A method for distinguishing healthy individuals from individuals having infectious or inflammatory conditions
Chang et al. Increase diagnostic efficacy by combined use of fingerprint markers in mass spectrometry—plasma peptidomes from nasopharyngeal cancer patients for example
US11435354B2 (en) Adenocarcinoma detection method
CN111065922A (zh) 肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标
US20190375842A1 (en) Check point inhibition in organ fibrosis
WO2023143650A1 (en) Method for determination of mutated form of mucin-1 protein in a biological sample
JP2005510725A (ja) アルツハイマー病を予測するフィブロネクチン前駆体バイオポリマーマーカー
Klein et al. Mischak, H., Peng, X.-R., Bascands, J.-L., and Schanstra, JP (2016) Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney International, 90 (5), pp. 1045-1055.
HK40029189A (en) Proadrenomedullin as indicator for renal replacement therapy in critically ill patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Burke, UK

Applicant after: Autism Biodiagnosis Ltd

Address before: London, England

Applicant before: Autism Biodiagnosis Ltd

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150916

Termination date: 20181213